Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Northwest Biotherapeutics (NWBO) just unveiled an announcement.
Pat Sarma has been appointed as a Class II director and member of the Audit, Compensation, and Conflicts Committees, effective March 18, 2024. His appointment came with no prior arrangements and is free from any related-party transactions requiring disclosure. As an independent director, Sarma will receive the same compensation as other non-employee directors of the company.
For detailed information about NWBO stock, go to TipRanks’ Stock Analysis page.